Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy
Selenophenes: Introducing a New Element into the Core of Non-Steroidal Estrogen Receptor Ligands
作者:Silong Zhang、Zhiyong Wang、Zhiye Hu、Changhao Li、Chu Tang、Kathryn E. Carlson、Junjie Luo、Chune Dong、John A. Katzenellenbogen、Jian Huang、Hai-Bing Zhou
DOI:10.1002/cmdc.201600593
日期:2017.2.3
marked effect on their binding affinities. The compound bis(2‐fluoro‐4‐hydroxyphenyl)selenophene (2 f) has the highest relative binding affinity (RBA) of 24.3 for ERβ. In transcription assays, most selenophenes were found to exhibit partial to full agonist activity for both ER subtypes, with compounds bis(2‐methyl‐4‐hydroxyphenyl)selenophene (2 b), bis(4‐fluoro‐3‐hydroxyphenyl)3‐bromoselenophene (6 f),
Rational design and optimization of selenophenes with basic side chains as novel potent selective estrogen receptor modulators (SERMs) for breast cancer therapy
Selenophenes with basic side chains showed excellent antagonist activity for ERs and increased antiproliferative activity than that of 4OHT in MCF-7 cells.